Search research articles
Contact Us
Filters
Showing results (571-580 of 721) with videos related to
Page
of 73
Sort By:
European Radiology
|
April 29, 2021
Prospective comparison of the diagnostic accuracy of 18F-FDG PET/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patients
Nils Martin Bruckmann, Julian Kirchner, Lale Umutlu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 18, 2024
Differences and Common Ground in <sup>177</sup>Lu-PSMA Radioligand Therapy Practice Patterns: International Survey of 95 Theranostic Centers
Andrea Farolfi, Wesley R Armstrong, Loic Djaileb, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 25, 2026
SSTR-Targeted Radiotheranostics in Breast Cancer: A Comparison of [<sup>68</sup>Ga]Ga-DOTATOC and [<sup>68</sup>Ga]Ga-SSO120 with [<sup>18</sup>F]FDG PET
Alina T Küper, Lalith Kumar Shiyam Sundar, Loíc Djaileb, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
April 30, 2021
FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials
Dominic Kaddu-Mulindwa, Bettina Altmann, Gerhard Held, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
January 23, 2022
Perspective paper about the joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[<sup>18</sup>F]FDG-PET/CT external beam radiation treatment planning in lung cancer
Sofia C Vaz, Judit A Adam, Roberto C Delgado Bolton, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 28, 2020
Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era
Víctor Rodriguez-Freixinos, Jaume Capdevila, Marianne Pavel, et al.
The Lancet. Oncology
|
May 29, 2025
Health-related quality of life, pain, and symptomatic skeletal events with [<sup>177</sup>Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial
Karim Fizazi, Michael J Morris, Neal D Shore, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 1, 2023
SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors
Thomas A Hope, Martin Allen-Auerbach, Lisa Bodei, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 29, 2023
Evaluation of [<sup>68</sup>Ga]-DOTATOC PET/MRI in Patients with Meningioma of the Subcranial and Intraorbital Space
Aleksandar Milosevic, Hanna Styczen, Johannes Grueneisen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 16, 2023
<sup>68</sup>Ga-Labeled Fibroblast Activation Protein Inhibitor (<sup>68</sup>Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the <sup>68</sup>Ga-FAPI PET Observational Trial
Lukas Kessler, Nader Hirmas, Kim M Pabst, et al.
Page
of 73
Search research articles
Search
Showing results (571-580 of 721) with videos related to
Sort By:
Page
of 73
European Radiology
|
April 29, 2021
Prospective comparison of the diagnostic accuracy of 18F-FDG PET/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patients
Nils Martin Bruckmann, Julian Kirchner, Lale Umutlu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 18, 2024
Differences and Common Ground in <sup>177</sup>Lu-PSMA Radioligand Therapy Practice Patterns: International Survey of 95 Theranostic Centers
Andrea Farolfi, Wesley R Armstrong, Loic Djaileb, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 25, 2026
SSTR-Targeted Radiotheranostics in Breast Cancer: A Comparison of [<sup>68</sup>Ga]Ga-DOTATOC and [<sup>68</sup>Ga]Ga-SSO120 with [<sup>18</sup>F]FDG PET
Alina T Küper, Lalith Kumar Shiyam Sundar, Loíc Djaileb, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
April 30, 2021
FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials
Dominic Kaddu-Mulindwa, Bettina Altmann, Gerhard Held, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
January 23, 2022
Perspective paper about the joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[<sup>18</sup>F]FDG-PET/CT external beam radiation treatment planning in lung cancer
Sofia C Vaz, Judit A Adam, Roberto C Delgado Bolton, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 28, 2020
Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era
Víctor Rodriguez-Freixinos, Jaume Capdevila, Marianne Pavel, et al.
The Lancet. Oncology
|
May 29, 2025
Health-related quality of life, pain, and symptomatic skeletal events with [<sup>177</sup>Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial
Karim Fizazi, Michael J Morris, Neal D Shore, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 1, 2023
SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors
Thomas A Hope, Martin Allen-Auerbach, Lisa Bodei, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 29, 2023
Evaluation of [<sup>68</sup>Ga]-DOTATOC PET/MRI in Patients with Meningioma of the Subcranial and Intraorbital Space
Aleksandar Milosevic, Hanna Styczen, Johannes Grueneisen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 16, 2023
<sup>68</sup>Ga-Labeled Fibroblast Activation Protein Inhibitor (<sup>68</sup>Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the <sup>68</sup>Ga-FAPI PET Observational Trial
Lukas Kessler, Nader Hirmas, Kim M Pabst, et al.
Page
of 73